No, many OTC stocks become vastly overpriced and then collapse. It comes with the territory.
And as for the posts this morning regarding Biologx, that poster should do some basic DD. The folks at Biologx have very clearly disavowed ANY connection to SSOF and have threatened to prosecute anyone alleging that such a connection exists.
Is that what all of this is about? Synthetic insulin is the old story here, joining swiss watches, video sharing, Virgin Islands pot spas, cannabis derivatives, greek food, oil equipment and oil drilling on the scrap heap of PROW/MBHC/MMHC/SSOF "mergers" that have been rescinded (if they were ever real to begin with).
Basic DD here would be to (a) learn about and understand the A-1 preferred shares and (b) figure out who owns them. But you can't learn (b), because SSOF is not filing anything. Is Jackson Morris still the lawyer filing paperwork with the incorporation folks? Maybe that would be an angle to track down? Is there any litigation associated with debts that need to get converted into shares (the typical way free-trading shares get issued by this ticker as an end run around Rule 144 -- Morris's company is called Rule 144 Solutions if I remember correctly).
As far as I can tell, SSOF is just doing its thing -- running up as high as it can before people stop buying it. It could easily double from here if there is enough promotion. But $50M is a very impressive market cap for a $300K shell with a troubled history. A double would put it at $100M. Eventually you need to have a real business to sustain those sorts of market caps.
I am obviously NOT an investment advisor.
